Nu-Med Plus, Inc.
NUMD
Other OTC0.01
USD
- -
- -
Nu-Med Plus, Inc.
NUMD
(Other OTC)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Nu-Med Plus, Inc. (NUMD) develops, enhances, and commercializes medical devices focused on nitric oxide delivery systems worldwide; its core products include a nitric oxide generating formulation, hospital bedside nitric oxide delivery systems, clinical units for medical clinics and rehabilitation centers, mobile rechargeable and portable devices to deliver inhaled nitric oxide gas, and research-grade nitric oxide systems. The company targets hospitals, health systems, clinics, rehabilitation centers, and research institutions, serving therapeutic applications such as neonatal hypoxia-ischemia, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and other pulmonary conditions benefiting from vasodilation and improved oxygenation. Founded in 2011 and headquartered at 640 Belle Terre Road, Building 2 East, Port Jefferson, New York, the firm operates primarily in the healthcare equipment segment of the medical devices industry with a small team of two employees. In recent developments, Nu-Med Plus reported a net loss of $43,564 for the nine months ended September 30, 2025, with no revenue generated as product development remains suspended pending approximately $1.2 million in additional funding over the next 12 months to cover overhead, operations, and advancement of its proprietary nitric oxide technologies. The company continues to emphasize its strategy of on-site nitric oxide generation to offer cost-effective alternatives to single-source market products like Inomax, positioning for potential partnerships with gas suppliers amid expanding medical applications, though it faces substantial going concern doubts without new capital via equity sales or shareholder loans. No acquisitions, partnerships, new product launches, or reorganizations have been announced in the last 1-2 years, with focus remaining on regulatory pathways including FDA approvals for hospital, clinical, and portable units.